Skip to Content

'
Eleni Efstathiou, MD, PhD

Present Title & Affiliation

Primary Appointment

Associate Professor, Department of Genitourinary Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX

Dual/Joint/Adjunct Appointment

Assistant Professor, University of Athens School of Medicine, Athens, Greece

Office Address

The University of Texas MD Anderson Cancer Center
1155 Pressler Blvd.
Unit Number: 1374
Houston, TX 77030
Room Number: CPB7.3518
Phone: 713 563 0894
Fax: 713 745 0422

Education & Training

Degree-Granting Education

2004 National and Kapodistrian University of Athens Greece School of Medicine, Athens, Greece, PHD, Medicine
1995 National and Kapodistrian University of Athens School of Medicine, Athens, Greece, MD, Medicine

Postgraduate Training

2004-2007 Postdoctoral Fellowship, The University of Texas MD Anderson Cancer Center, Houston, TX
1997-2004 Clinical Residency, National and Kapodistrian University of Athens School of Medicine, Athens, Greece
1996-1997 Clinical Internship, Public Health System of Greece – Rural Service, Athens, Greece

Board Certifications

2/2007 ECFMG
12/2003 Internal Medicine (Greece)

Experience/Service

Academic Appointments

Assistant Professor, Department of Genitourinary Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, 4/2009-5/2013
Instructor, National and Kapodistrian University of Athens Greece, Athens, Greece, 3/2008-7/2012
Assistant Professor, Department of Genitourinary Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, 3/2008-4/2009
Instructor, Department of Genitourinary Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, 6/2006-2/2008
Postdoctoral Fellow, Department of Genitourinary Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, 2004-5/2006

Administrative Appointments/Responsibilities

Member, National Ethics Committee, Athens, Greece, 2010-present
Member, National Committee for Therapy Guidelines in Oncology, Athens, Greece, 2010-present

Honors and Awards

2008 Young Investigator Award, Prostate Cancer Foundation

Professional Memberships

American Society of Clinical Oncology
Junior Member, 1/2009-present

Selected Publications

Peer-Reviewed Original Research Articles

1. Droz J-P, Aapro M, Balducci L, Boyle H, Van den Broeck T, Cathcart P, Dickinson L, Efstathiou E, Emberton M, Fitzpatrick, Heidenreich A, Hughes S, Joniau S, Kattan M, Mottet N, Oudard S, Payne H, Saad F, Sugihara T. Management of prostate cancer in senior adults: updated recommendations of a working group of the International Society of Geriatric Oncology (SIOG). Lancet Oncol. In Press.
2. Liu XD, Yao J, Tripathi DN, Ding Z, Xu Y, Sun M, Zhang J, Bai S, German P, Hoang A, Zhou L, Jonasch D, Zhang X, Conti CJ, Efstathiou E, Tannir NM, Eissa NT, Mills GB, Walker CL, Jonasch E. Autophagy mediates HIF2α degradation and suppresses renal tumorigenesis. Oncogene. e-Pub 7/7/2014. PMID: 24998849.
3. Fitzpatrick JM, Bellmunt J, Fizazi K, Heidenreich A, Sternberg CN, Tombal B, Alcaraz A, Bahl A, Bracarda S, Di Lorenzo G, Efstathiou E, Finn SP, Fosså S, Gillessen S, Kellokumpu-Lehtinen PL, Lecouvet FE, Oudard S, de Reijke TM, Robson CN, De Santis M, Seruga B, de Wit R. Optimal management of metastatic castration-resistant prostate cancer: Highlights from a European Expert Consensus Panel. Eur J Cancer 50(9):1617-1627, 6/2014. e-Pub 4/3/2014. PMID: 24703899.
4. Efstathiou E, Titus M, Wen S, Hoang A, Karlou M, Ashe R, Tu SM, Aparicio A, Troncoso P, Mohler J, Logothetis CJ. Molecular characterization of enzalutamide-treated bone metastatic castration-resistant prostate cancer. Eur Urol. e-Pub 5/29/2014. PMID: 24882673.
5. Li L, Chang W, Yang G, Ren C, Park S, Karantanos T, Karanika S, Wang J, Yin J, Shah PK, Takahiro H, Dobashi M, Zhang W, Efstathiou E, Maity SN, Aparicio AM, Li Ning Tapia EM, Troncoso P, Broom B, Xiao L, Lee HS, Lee JS, Corn PG, Navone N, Thompson TC. Targeting poly(ADP-Ribose) polymerase and the c-Myb-regulated DNA damage response pathway in castration-resistant prostate cancer. Sci Signal 7(326):ra47, 5/20/2014. e-Pub 5/20/2014. PMID: 24847116.
6. Wilton JH, Titus MA, Efstathiou E, Fetterly GJ, Mohler JL. Androgenic biomarker profiling in human matrices and cell culture samples using high throughput, electrospray tandem mass spectrometry. Prostate 74(7):722-31, 5/2014. PMID: 24847527.
7. Rathkopf DE, Smith MR, de Bono JS, Logothetis CJ, Shore ND, de Souza P, Fizazi K, Mulders PF, Mainwaring P, Hainsworth JD, Beer TM, North S, Fradet Y, Van Poppel H, Carles J, Flaig TW, Efstathiou E, Yu EY, Higano CS, Taplin ME, Griffin TW, Todd MB, Yu MK, Park YC, Kheoh T, Small EJ, Scher HI, Molina A, Ryan CJ, Saad F. Updated Interim Efficacy Analysis and Long-term Safety of Abiraterone Acetate in Metastatic Castration-resistant Prostate Cancer Patients Without Prior Chemotherapy (COU-AA-302). Eur Urol. e-Pub 3/6/2014. PMID: 24647231.
8. Arora VK, Schenkein E, Murali R, Subudhi SK, Wongvipat J, Balbas MD, Shah N, Cai L, Efstathiou E, Logothetis C, Zheng D, Sawyers CL. Glucocorticoid receptor confers resistance to antiandrogens by bypassing androgen receptor blockade. Cell 155(6):1309-22, 12/5/2013. PMID: 24315100.
9. Araujo JC, Trudel GC, Saad F, Armstrong AJ, Yu EY, Bellmunt J, Wilding G, McCaffrey J, Serrano SV, Matveev VB, Efstathiou E, Oudard S, Morris MJ, Sizer B, Goebell PJ, Heidenreich A, de Bono JS, Begbie S, Hong JH, Richardet E, Gallardo E, Paliwal P, Durham S, Cheng S, Logothetis CJ. Docetaxel and dasatinib or placebo in men with metastatic castration-resistant prostate cancer (READY): a randomised, double-blind phase 3 trial. Lancet Oncol 14(13):1307-16, 12/2013. e-Pub 11/2013. PMID: 24211163.
10. Som A, Xiao L, Zhu R, Guo CC, Xiao L, Rao P, Efstathiou E, Matin A, Tu SM. Clinically atypical seminomas with yolk sac tumor features. Can J Urol 20(4):6860-7, 8/2013. PMID: 23930614.
11. Logothetis CJ, Gallick GE, Maity SN, Kim J, Aparicio A, Efstathiou E, Lin SH. Molecular classification of prostate cancer progression: Foundation for marker-driven treatment of prostate cancer. Cancer Discov. e-Pub 6/2013. PMCID: PMC3926428.
12. Ryan CJ, Smith MR, de Bono JS, Molina A, Logothetis CJ, de Souza P, Fizazi K, Mainwaring P, Piulats JM, Ng S, Carles J, Mulders PF, Basch E, Small EJ, Saad F, Schrijvers D, Van Poppel H, Mukherjee SD, Suttmann H, Gerritsen WR, Flaig TW, George DJ, Yu EY, Efstathiou E, Pantuck A, Winquist E, Higano CS, Taplin ME, Park Y, Kheoh T, Griffin T, Scher HI, Rathkopf DE, COU-AA-302 Investigators. Abiraterone in metastatic prostate cancer without previous chemotherapy. N Engl J Med 368(2):138-48, 1/10/2013. e-Pub 12/10/2012. PMCID: PMC3683570.
13. Efstathiou E, Karlou M, Wen S, Hoang A, Pettaway CA, Pisters LL, Maity S, Troncoso P, Logothetis CJ. Integrated hedgehog signaling is induced following castration in human and murine prostate cancers. Prostate 73(2):153-61, 1/2013. e-Pub 7/2012. PMID: 22753310.
14. Mourmouris P, Efstathiou E, Papatsoris A. Androgen deprivation therapy and cardiovascular risk. Nephrourol Mon 5(1):653-4, 2013. e-Pub 12/15/2012. PMCID: PMC3614327.
15. Logothetis CJ, Basch E, Molina A, Fizazi K, North SA, Chi KN, Jones RJ, Goodman OB, Mainwaring PN, Sternberg CN, Efstathiou E, Gagnon DD, Rothman M, Hao Y, Liu CS, Kheoh TS, Haqq CM, Scher HI, de Bono JS. Effect of abiraterone acetate and prednisone compared with placebo and prednisone on pain control and skeletal-related events in patients with metastatic castration-resistant prostate cancer: exploratory analysis of data from the COU-AA-301 randomised trial. Lancet Oncol 13(12):1210-7, 12/2012. e-Pub 11/9/2012. PMID: 23142059.
16. Karlou M, Lu JF, Wu G, Maity S, Tzelepi V, Navone NM, Hoang A, Logothetis CJ, Efstathiou E. Hedgehog signaling inhibition by the small molecule smoothened inhibitor GDC-0449 in the bone forming prostate cancer xenograft MDA PCa 118b. Prostate 72(15):1638-47, 11/2012. e-Pub 3/27/2012. PMID: 22457212.
17. Som A, Zhu R, Guo CC, Efstathiou E, Xiao L, Pisters LL, Matin A, Tu SM. Recurrent seminomas: Clinical features and biologic implications. Urol Oncol 30(4):494-501, Jul-Aug, 7/2012. e-Pub 9/6/2010. PMID: 20822932.
18. Sircar K, Huang H, Hu L, Cogdell D, Dhillon J, Tzelepi V, Efstathiou E, Koumakpayi IH, Saad F, Luo D, Bismar TA, Aparicio A, Troncoso P, Navone N, Zhang W. Integrative molecular profiling reveals asparagine synthetase is a target in castration-resistant prostate cancer. Am J Pathol 180(3):895-903, 3/2012. e-Pub 1/11/2012. PMID: 22245216.
19. Wan X, Liu J, Lu JF, Tzelepi V, Yang J, Starbuck MW, Diao L, Wang J, Efstathiou E, Vazquez ES, Troncoso P, Maity SN, Navone NM. Activation of β-catenin signaling in androgen receptor-negative prostate cancer cells. Clin Cancer Res 18(3):726-36, 2/1/2012. PMCID: PMC3271798.
20. Efstathiou E, Titus M, Tsavachidou D, Tzelepi V, Wen S, Hoang A, Molina A, Chieffo N, Smith LA, Karlou M, Troncoso P, Logothetis CJ. Effects of abiraterone acetate on androgen signaling in castrate-resistant prostate cancer in bone. J Clin Oncol 30(6):637-43, 2/20/2012. e-Pub 12/19/2011. PMCID: PMC3295561.
21. Tzelepi V, Zhang J, Lu JF, Kleb B, Wu G, Wan X, Hoang A, Efstathiou E, Sircar K, Navone NM, Troncoso P, Liang S, Logothetis CJ, Maity SN, Aparicio AM. Modeling a lethal prostate cancer variant with small-cell carcinoma features. Clin Cancer Res 18(3):666-77, 2/2012. e-Pub 12/2011. PMCID: PMC3923417.
22. Dimopoulos S, Eleftherakis E, Charitos C, Sakellaridis T, Sinapidis D, Kostis E, Toumanidis S, Efstathiou E. Bartonella quintana endocarditis as a cause of severe aortic insufficiency and heart failure. Hellenic J Cardiol 53(6):476-9, Nov-Dec, 2012. PMID: 23178432.
23. Sircar K, Huang H, Hu L, Liu Y, Dhillon J, Cogdell D, Aprikian A, Efstathiou E, Navone N, Troncoso P, Zhang W. Mitosis phase enrichment with identification of mitotic centromere-associated kinesin as a therapeutic target in castration-resistant prostate cancer. PLoS One 7(2):e31259, 2012. e-Pub 2/17/2012. PMCID: PMC3281954.
24. Staquicini FI, Cardó-Vila M, Kolonin MG, Trepel M, Edwards JK, Nunes DN, Sergeeva A, Efstathiou E, Sun J, Almeida NF, Tu SM, Botz GH, Wallace MJ, O'Connell DJ, Krajewski S, Gershenwald JE, Molldrem JJ, Flamm AL, Koivunen E, Pentz RD, Dias-Neto E, Setubal JC, Cahill DJ, Troncoso P, Do KA, Logothetis CJ, Sidman RL, Pasqualini R, Arap W. Vascular ligand-receptor mapping by direct combinatorial selection in cancer patients. Proc Natl Acad Sci U S A 108(46):18637-42, 11/15/2011. e-Pub 11/2/2011. PMCID: PMC3219136.
25. Ryan CJ, Shah S, Efstathiou E, Smith MR, Taplin ME, Bubley GJ, Logothetis CJ, Kheoh T, Kilian C, Haqq CM, Molina A, Small EJ. Phase II study of abiraterone acetate in chemotherapy-naive metastatic castration-resistant prostate cancer displaying bone flare discordant with serologic response. Clin Cancer Res 17(14):4854-61, 7/15/2011. e-Pub 6/1/2011. PMCID: PMC3657705.
26. Tzelepi V, Efstathiou E, Wen S, Troncoso P, Karlou M, Pettaway CA, Pisters LL, Hoang A, Logothetis CJ, Pagliaro LC. Persistent, biologically meaningful prostate cancer after 1 year of androgen ablation and docetaxel treatment. J Clin Oncol 29(18):2574-81, 6/20/2011. e-Pub 5/23/2011. PMCID: PMC3138635.
27. Tzelepi V, Karlou M, Wen S, Hoang A, Logothetis C, Troncoso P, Efstathiou E. Expression of hedgehog pathway components in prostate carcinoma microenvironment: shifting the balance towards autocrine signalling. Histopathology 58(7):1037-47, 6/2011. PMID: 21707705.
28. de Bono JS, Logothetis CJ, Molina A, Fizazi K, North S, Chu L, Chi KN, Jones RJ, Goodman OB, Saad F, Staffurth JN, Mainwaring P, Harland S, Flaig TW, Hutson TE, Cheng T, Patterson H, Hainsworth JD, Ryan CJ, Sternberg CN, Ellard SL, Fléchon A, Saleh M, Scholz M, Efstathiou E, Zivi A, Bianchini D, Loriot Y, Chieffo N, Kheoh T, Haqq CM, Scher HI, COU-AA-301 Investigators. Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med 364(21):1995-2005, 5/26/2011. PMCID: PMC3471149.
29. Drivalos A, Papatsoris AG, Chrisofos M, Efstathiou E, Dimopoulos MA. The role of the cell adhesion molecules (integrins/cadherins) in prostate cancer. Int Braz J Urol 37(3):302-6, May-Jun, 5/2011. PMID: 21756376.
30. Bournakis E, Efstathiou E, Varkaris A, Wen S, Chrisofos M, Deliveliotis C, Alamanis C, Anastasiou I, Constantinides C, Bamias A, Dimopoulos MA. Time to castration resistance is an independent predictor of castration-resistant prostate cancer survival. Anticancer Res 31(4):1475-82, 4/2011. PMID: 21508406.
31. Mountzios I, Bournakis E, Efstathiou E, Varkaris A, Wen S, Chrisofos M, Deliveliotis C, Alamanis C, Anastasiou I, Constantinides C, Karadimou A, Tsiatas M, Papadimitriou C, Bamias A, Dimopoulos MA. Intermittent docetaxel chemotherapy in patients with castrate-resistant prostate cancer. Urology 77(3):682-7, 3/2011. e-Pub 1/22/2011. PMID: 21256546.
32. Efstathiou E, Titus M, Tsavachidou D, Tzelepi V, Wen S, Hoang A, Molina A, Chieffo N, Smith LA, Karlou M, Troncoso P, Logothetis CJ. Effects of abiraterone acetate on androgen signaling in castrate-resistant prostate cancer in bone. J Clin Oncol 30(6):637-43, 2011.
33. Eleutherakis-Papaiakovou E, Kostis E, Migkou M, Christoulas D, Terpos E, Gavriatopoulou M, Roussou M, Bournakis E, Kastritis E, Efstathiou E, Dimopoulos MA, Papadimitriou CA. Prophylactic antibiotics for the prevention of neutropenic fever in patients undergoing autologous stem-cell transplantation: results of a single institution, randomized phase 2 trial. Am J Hematol 85(11):863-7, 11/2010. PMID: 20882526.
34. Bourdoumis A, Papatsoris AG, Chrisofos M, Efstathiou E, Skolarikos A, Deliveliotis C. The novel prostate cancer antigen 3 (PCA3) biomarker. Int Braz J Urol 36(6):665-8; discussion 669, Nov-Dec, 11/2010. PMID: 21176272.
35. Dimopoulos MA, Kastritis E, Christoulas D, Migkou M, Gavriatopoulou M, Gkotzamanidou M, Iakovaki M, Matsouka C, Mparmparoussi D, Roussou M, Efstathiou E, Terpos E. Treatment of patients with relapsed/refractory multiple myeloma with lenalidomide and dexamethasone with or without bortezomib: prospective evaluation of the impact of cytogenetic abnormalities and of previous therapies. Leukemia 24(10):1769-78, 10/2010. e-Pub 8/26/2010. PMID: 20739955.
36. Dimopoulos MA, Christoulas D, Roussou M, Kastritis E, Migkou M, Gavriatopoulou M, Matsouka C, Mparmparoussi D, Psimenou E, Grapsa I, Efstathiou E, Terpos E. Lenalidomide and dexamethasone for the treatment of refractory/relapsed multiple myeloma: dosing of lenalidomide according to renal function and effect on renal impairment. Eur J Haematol 85(1):1-5, 7/2010. e-Pub 2/20/2010. PMID: 20192988.
37. Efstathiou E, Abrahams NA, Tibbs RF, Wang X, Pettaway CA, Pisters LL, Mathew PF, Do KA, Logothetis CJ, Troncoso P. Morphologic characterization of preoperatively treated prostate cancer: Toward a post-therapy histologic classification. Eur Urol 57(6):1030-8, 6/2010. e-Pub 10/2009. PMCID: PMC2962710.
38. Scher HI, Beer TM, Higano CS, Anand A, Taplin ME, Efstathiou E, Rathkopf D, Shelkey J, Yu EY, Alumkal J, Hung D, Hirmand M, Seely L, Morris MJ, Danila DC, Humm J, Larson S, Fleisher M, Sawyers CL, Prostate Cancer Foundation/Department of Defense Prostate Cancer Clinical Trials Consortium. Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1-2 study. Lancet 375(9724):1437-46, 4/24/2010. e-Pub 4/14/2010. PMCID: PMC2948179.
39. Efstathiou E, Logothetis CJ. A new therapy paradigm for prostate cancer founded on clinical observations. Clin Cancer Res 16(4):1100-7, 2/15/2010. e-Pub 2/9/2010. PMID: 20145177.
40. Efstathiou E, Abrahams NA, Tibbs RF, Want X, Pettaway CA, Pisters LL, Mathew PF, Do KA, Logothetis CJ, Troncoso P. Morphologic characterization of preoperatively treated prostate cancer: Toward a post-therapy histologic classification. Eur Urol 57(6):1030-8, 2010.
41. Tsavachidou D, McDonnell TJ, Wen S, Wang X, Vakar-Lopez F, Pisters LL, Pettaway CA, Wood CG, Do KA, Thall PF, Stephens C, Efstathiou E, Taylor R, Menter DG, Troncoso P, Lippman SM, Logothetis CJ, Kim J. Selenium and vitamin E: Cell type- and intervention-specific tissue effects in prostate cancer. J Natl Cancer Inst 101(5). e-Pub 2/2009. PMID: 19244175.
42. Gorlov IP, Byun J, Gorlova OY, Aparicio AM, Efstathiou E, Logothetis CJ. Candidate pathways and genes for prostate cancer: a meta-analysis of gene expression data. BMC Med Genomics 2:48, 2009. PMCID: PMC2731785.
43. Tsao CC, Teh BT, Jonasch E, Shreiber-Agus N, Efstathiou E, Hoang A, Czerniak B, Logothetis C, Corn PG. Inhibition of Mxi1 suppresses HIF-2alpha-dependent renal cancer tumorigenesis. Cancer Biol Ther 7(10). e-Pub 10/3/2008. PMID: 19018165.
44. Skordis N, Ioannou YS, Kyriakou A, Savva SC, Efstathiou E, Savvides I, Christou S. Effect of bisphosphonate treatment on bone mineral density in patients with thalassaemia major. Pediatr Endocrinol Rev 6S(1):144-8, 10/2008. PMID: 19337169.
45. Skordis N, Efstathiou E, Kyriakou A, Toumba M. Hormonal dysregulation and bones in thalassaemia--an overview. Pediatr Endocrinol Rev 6S(1):107-15, 10/2008. PMID: 19337163.
46. Li ZG, Mathew P, Yang J, Starbuck MW, Zurita AJ, Liu J, Sikes C, Multani AS, Efstathiou E, Lopez A, Wang J, Fanning TV, Prieto VG, Kundra V, Vazquez ES, Troncoso P, Raymond AK, Logothetis CJ, Lin SH, Maity S, Navone NM. Androgen receptor-negative human prostate cancer cells induce osteogenesis in mice through FGF9-mediated mechanisms. J Clin Invest 118(8):2697-710, 8/2008. PMCID: PMC2447924.
47. Yannakoulia M, Papanikolaou K, Hatzopoulou I, Efstathiou E, Papoutsakis C, Dedoussis GV. Association between family divorce and children's BMI and meal patterns: the GENDAI Study. Obesity (Silver Spring) 16(6):1382-7, 6/2008. e-Pub 3/2008. PMID: 18369339.
48. Papadimitriou C, Dafni U, Anagnostopoulos A, Vlachos G, Voulgaris Z, Rodolakis A, Aravantinos G, Bamias A, Bozas G, Kiosses E, Gourgoulis GM, Efstathiou E, Dimopoulos MA. High-dose melphalan and autologous stem cell transplantation as consolidation treatment in patients with chemosensitive ovarian cancer: results of a single-institution randomized trial. Bone Marrow Transplant 41(6):547-54, 3/2008. e-Pub 11/2007. PMID: 18026149.
49. Bozas G, Bamias A, Koutsoukou V, Efstathiou E, Gika D, Papadimitriou CA, Dimopoulos MA. Biweekly gemcitabine and cisplatin in platinum-resistant/refractory, paclitaxel-pretreated, ovarian and peritoneal carcinoma. Gynecol Oncol 104(3):580-5, 3/2007. e-Pub 10/17/2006. PMID: 17052747.
50. Efstathiou E, Dimopoulos MA, Bozas G, Kastritis E, Moulopoulos LA, Rodolakis A, Vlahos G, Gika D, Papadimitriou C, Bamias A. Advanced epithelial ovarian cancer in the elderly: chemotherapy tolerance and outcome. Anticancer Res 27(1B):611-7, Jan-Feb, 1/2007. PMID: 17348450.
51. Efstathiou E, Troncoso P, Wen S, Do KA, Pettaway CA, Pisters LL, McDonnell TJ, Logothetis CJ. Initial modulation of the tumor microenvironment accounts for thalidomide activity in prostate cancer. Clin Cancer Res 13(4):1224-31, 2007.
52. Efstathiou E, Logothetis CJ. Outliers in testicular cancer management. Oncology (CMPMedica) 20(12):1575-76, 2007.
53. Kambouri K, Gardikis S, Giatromanolaki A, Efstathiou E, Pitiakoudis M, Ipsilantis P, Botaitis S, Perente S, Antypas S, Polychronidis A, Sivridis E, Simopoulos C. Comparison of angiogenic activity after urethral reconstruction using free grafts and pedicle flap: an experimental study. Eur J Pediatr Surg 16(5):323-8, 10/2006. PMID: 17160776.
54. Bamias A, Papadimitriou C, Efstathiou E, Rodolakis A, Vlahos G, Voulgaris Z, Bozas G, Fountzilas G, Aravantinos G, Razis E, Gika D, Dimopoulos MA. Four cycles of paclitaxel and carboplatin as adjuvant treatment in early-stage ovarian cancer: a six-year experience of the Hellenic Cooperative Oncology Group. BMC Cancer 25(6):228, 9/2006. PMCID: PMC1592509.
55. Pectasides D, Fountzilas G, Aravantinos G, Kalofonos C, Efstathiou H, Farmakis D, Skarlos D, Pavlidis N, Economopoulos T, Dimopoulos MA. Advanced stage clear-cell epithelial ovarian cancer: The Hellenic cooperative oncology group experience. Gynecol Oncol 102(2):285-91, 8/2006.
56. Mauri D, Pentheroudakis G, Bafaloukos D, Pectasides D, Samantas E, Efstathiou E, Kalofonos HP, Syrigos K, Klouvas G, Papakostas P, Kosmidis P, Fountzilas G, Pavlidis N, Pavlidis N. Non-small cell lung cancer in the young: a retrospective analysis of diagnosis, management and outcome data. Anticancer Res 26(4B):3175-81, Jul-Aug, 7/2006. PMID: 16886653.
57. Kastritis E, Efstathiou E, Gika D, Bozas G, Koutsoukou V, Papadimitriou C, Pissakas G, Dimopoulos MA, Bamias A. Brain metastases as isolated site of relapse in patients with epithelial ovarian cancer previously treated with platinum and paclitaxel-based chemotherapy. Int J Gynecol Cancer 16(3):994-9, May-Jun, 2006. PMID: 16803475.
58. Bozas G, Dimopoulos MA, Kastritis E, Efstathiou E, Koutsoukou V, Rodolakis A, Vlahos G, Voulgaris Z, Papageorgiou T, Gika D, Papadimitriou C, Bamias A. Young age is associated with favorable characteristics but is not an independent prognostic factor in patients with epithelial ovarian cancer: a single institution experience. Oncology 70(4):265-72, 2006. e-Pub 8/2006. PMID: 16899981.
59. Psyrri A, Bamias A, Yu Z, Weinberger PM, Kassar M, Markakis S, Kowalski D, Efstathiou E, Camp RL, Rimm DL, Dimopoulos MA. Subcellular localization and protein levels of cyclin-dependent kinase inhibitor p27 independently predict for survival in epithelial ovarian cancer. Clin Cancer Res 11(23):8384-90, 12/2005. PMID: 16322299.
60. Kastritis E, Bamias A, Efstathiou E, Gika D, Bozas G, Zorzou P, Sarris K, Papadimitriou C, Dimopoulos MA. The outcome of advanced or recurrent non-squamous carcinoma of the uterine cervix after platinum-based combination chemotherapy. Gynecol Oncol 99(2):376-382, 11/2005. e-Pub 7/26/2005. PMID: 16051322.
61. Xiros N, Papacostas P, Economopoulos T, Samelis G, Efstathiou E, Kastritis E, Kalofonos H, Onyenadum A, Skarlos D, Bamias A, Gogas H, Bafaloukos D, Samantas E, Kosmidis P. Carboplatin plus gemcitabine in patients with inoperable or metastatic pancreatic cancer: a phase II multicenter study by the Hellenic Cooperative Oncology Group. Ann Oncol 5:773-9, 16, 5/2005.
62. Polychronidis A, Tsaroucha AK, Karayiannakis AJ, Perente S, Efstathiou E, Simopoulos C. Delayed perforation of the large bowel due to thermal injury during laparoscopic cholecystectomy. J Int Med Res 33(3):360-3, May-Jun, 5/2005. PMID: 15938598.
63. Zorzou MP, Efstathiou E, Galani E, Bozas G, Kastritis E, Papadimitriou C, Dimopoulos MA, Bamias A. A carboplatin hypersensitivity reactions: a single institution experience. J Chemother 17(1):104-10, 2005.
64. Pectasides D, Fountzilas G, Aravantinos G, Kalofonos HP, Efstathiou E, Salamalekis E, Farmakis D, Skarlos D, Briasoulis E, Economopoulos T, Dimopoulos MA. Advanced stage mucinous epithelial ovarian cancer: The Hellenic Cooperative Oncology Group experience. Gynecol Oncol 16(2):191-198, 2005.
65. Pectasides D, Aravantinos G, Fountzilas G, Kalofonos C, Efstathiou E, Karina M, Pavlidis N, Farmakis D, Economopoulos T, Dimopoulos MA. Brain metastases from epithelial ovarian cancer. The Hellenic Cooperative Oncology Group (HeCOG) experience and review of the literature. Anticancer Res 25(5):3553-8, Sep-Oct, 2005. PMID: 16101179.
66. Efstathiou E, Bozas G, Kostakopoulos A, Kastritis E, Deliveliotis C, Antoniou N, Skarlos D, Papadimitriou C, Dimopoulos MA, Bamias A. Combination of docetaxel, estramustine phosphate, and zoledronic acid in androgen-independent metastatic prostate cancer: efficacy, safety, and clinical benefit assessment. Urology 65(1):126-30, 2005.
67. Bamias A, Efstathiou E, Vassilakopoulou M, Koutsoukou V, Papadimitriou C, Rodolakis A Mitsibounas D, Vlahos G, Dimopoulos MA. Late relapse of epithelial ovarian cancer: a single institution experience. Eur J Gynaecol Oncol 26(4):439-42, 2005.
68. Chamilos G, Bamias A, Efstathiou E, Zorzou PM, Kastritis E, Kostis E, Papadimitriou C, Dimopoulos MA. Outpatient treatment of low-risk neutropenic fever in cancer patients using oral moxifloxacin. Cancer 103(12):2629-2635, 2005. PMID: 15856427.
69. Bafaloukos D, Tsoutsos D, Kalofonos H, Chalkidou S, Panagiotou P, Linardou E, Briassoulis E, Efstathiou E, Polyzos A, Fountzilas G, Christodoulou C, Kouroussis C, Iconomou T, Gogas H. Temozolomide and cisplatin versus temozolomide in patients with advanced melanoma: a randomized phase II study of the Hellenic Cooperative Oncology Group. Ann Oncol 16(6):950-957, 2005. e-Pub 4/2005. PMID: 15829494.
70. Bamias A, Efstathiou E, Moulopoulos LA, Gika D, Hamilos G, Zorzou MP, Kakoyiannis C, Kastritis E, Bozas G, Papadimitriou C, Dimopoulos MA. The outcome of elderly patients with advanced urothelial carcinoma after platinum-based combination chemotherapy. Ann Oncol 16(2):307-13, 2005.
71. Dimopoulou I, Efstathiou E, Samakovli A, Dafni U, Moulopoulos LA, Papadimitriou C, Lyberopoulos P, Kastritis E, Roussos C, and Dimopoulos MA.. A prospective study of lung toxicity in patients treated with gemcitabine and carboplatin: clinical, radiological and functional assessment. Ann Oncol 15(8):1250-1255, 2004. PMID: 15277266.
72. Zorzou MP, Stratigos A, Efstathiou E, and Bamias A. Exacerbation of psoriasis after treatment with an EGFR tyrosine kinase inhibitor. Acta Derm Venereol 84(4):308-309, 2004.
73. Linardou H, Aravantinos G, Efstathiou E, Kalofonos C, Anagnostopoulos A, Deliveliotis C, Bafaloukos D, Athanasios Dimopoulos M, and Bamias A. Gemcitabine and carboplatin combination as first-line treatment in elderly patients and those unfit for cisplatin-based chemotherapy with advanced bladder carcinoma: Phase II study of the Hellenic Cooperative Oncology Group. Urology 64(3), 2004.
74. Papadimitriou CA, Markaki S, Siapkaras J, Vlachos G, Efstathiou E, Grimani I, Hamilos G, Zorzou M, and Dimopoulos MA. Hormonal therapy with letrozole for relapsed epithelial ovarian cancer. Long term results of a phase II study. Oncology 66(2):112-117, 2004.
75. Dimopoulos MA, Hamilos G, Zomas A, Gika D, Efstathiou E, Grigoraki V, Poziopoulos C, Xilouri I, Zorzou MP, Anagnostopoulos N, and Anagnostopoulos A. Pulsed cyclophosphamide, thalidomide and dexamethasone: an oral regimen for previously treated patients with multiple myeloma. Hematol J 5(2):112-117, 2004.
76. Dimopoulos MA, Papadimitriou C, Hamilos G, Efstathiou E, Vlahos G, Rodolakis A, Aravantinos G, Kalofonos H, Kouroussis C, Gika D, Skarlos D, and Bamias A. Treatment of ovarian germ cell tumors with a 3-day bleomycin, etoposide, and cisplatin regimen: a prospective multicenter study. Gynecol Oncol 95(3):695-700, 2004.
77. Kroupis C, Lianidou E, Goutas N, Ladopoulou A, Konstantopoulou I, Pantazidis A, Yannoukakos D, Efstathiou E, Vourlidis N, and Tsionou C. Atypical medullary breast carcinoma in a family carrying the 5382insC BRCA-1 mutation. Breast J 9(3):260-262, 2003.
78. Dimopoulos MA, Hamilos G, Efstathiou E, Siapkaras I, Matsouka C, Gika D, Grigoraki V, Papadimitriou C, Mitsibounas D, and Anagnostopoulos N. Treatment of Waldenstrom’s macroglobulinemia with the combination of fludarabine and cyclophosphamide. Leuk Lymphoma 44(6):993-996, 2003.
79. Ladopoulou A, Kroupis C, Konstantopoulou I, Ioannidou-Mouzaka L, Schofield AC, Pantazidis A, Armaou S, Tsiagas I, Lianidou E, Efstathiou E, Tsionou C, Panopoulos C, Mihalatos M, Nasioulas G, Skarlos D, Haites NE, Fountzilas G, Pandis N, Yannoukakos D. Germ line BRCA1 & BRCA2 mutations in Greek breast/ ovarian cancer families: 5382insC is the most frequent mutation observed. Cancer Lett 185(1):61-70, 11/2002. PMID: 12142080.
80. Ladopoulou A, Konstantopoulou I, Armaou S, Efstathiou E, Mihalatos M, Nasioulas G, Bardi G, Pandis N, Yannoukakos D, Athens; Hellenic Cooperative Oncology Group. A change in the last base of BRCA1 exon 23, 5586G--> A, results in abnormal RNA splicing. Cancer Genet Cytogen 134(2):175-177, 2002.
81. Dimopoulos MA, Papadimitriou CA, Sarris K, Aravantinos G, Kalofonos C, Gika D, Gourgoulis GM, Efstathiou E, Skarlos D, and Bafaloukos D. Combination of ifosfamide, paclitaxel, and cisplatin for the treatment of metastatic and recurrent carcinoma of the uterine cervix: a phase II study of the Hellenic Cooperative Oncology Group. Gynecol Oncol 85(3):476-482, 2002.
82. Christodoulou C, Klouvas G, Efstathiou E, Zervakis D, Papazachariou E, Plyta M, and Skarlos DV. Effectiveness of the MSC cold cap system in the prevention of chemotherapy-induced alopecia. Oncology 62(2):97-102, 2002.
83. Dimopoulos MA, Zervas C, Zomas A, Hamilos G, Gika D, Efstathiou E, Panayiotidis P, Vervessou E, Anagnostopouos N, Christakis J. Extended rituximab therapy for previously untreated patients with Waldenström's macroglobulinemia. Clin Lymphoma 3(3):163-6, 2002.
84. Konstantopoulou I, Kroupis C, Ladopoulou A, Pantazidis A, Boumba D, Lianidou ES, Petersen MB, Florentin L, Chiotellis E, Nounesis G, Efstathiou E, Skarlos D, Tsionou C, Fountzilas G, and Yannoukakos D. BRCA1 mutation analysis in breast/ ovarian cancer families from Greece. Hum Mutat 16(3):272-273, 2000.
85. Janinis J, Efstathiou E, Panopoulos C, Samantas E, Aravantinos G, Christodoulou C, and Skarlos D. Phase II study of temozolomide in patients with relapsing high grade glioma and poor performance status. Med Οncology 17(2):106-110, 2000.

Invited Articles

1. Logothetis CJ, Efstathiou E, Manuguid F, Kirkpatrick P. Abiraterone acetate. Nat Rev Drug Discov 10(8):573-4, 8/2011. e-Pub 8/2011. PMID: 21804589.
2. Karlou M, Tzelepi V, Efstathiou E. Therapeutic targeting of the prostate cancer microenvironment. Nat Rev Urol 7(9):494-509, 9/2010. PMID: 20818327.
3. Efstathiou E, Logothetis CJ. Prostate cancer: Thalidomide for prostate cancer: is there progress? Nat Rev Urol 6(5):248-50, 5/2009. PMID: 19424170.
4. Efstathiou E, Logothetis CJ. Review of late complications of treatment and late relapse in testicular cancer. J Natl Compr Canc Netw 4(10):1059-70, 11/2006. PMID: 17112453.

Editorials

1. Efstathiou E, Kim J, Logothetis CJ. Informative clinical investigation: a demanding taskmaster. J Clin Oncol 27(30):4937-8, 10/20/2009. e-Pub 8/31/2009. PMID: 19720892.
Other Articles
1. Terpos E, Efstathiou E, Christoulas D, Roussou M, Katodritou E, Dimopoulos MA. RANKL inhibition: Clinical implications for the management of patients with multiple myeloma and solid tumors with bone metastases. Expert Opin Biol Ther 9(4):465-79, 4/2009. PMID: 19344283.

Abstracts

1. Titus M, Logothetis CJ, Perabo F, Troncoso P, deHaas-Amatsaleh A, Ouatas T, Efstathiou E. Enzalutamide (ENZA) in combination with abiraterone acetate (AA) in bone metastatic castration resistant prostate cancer (mCRPC). J Clin Oncol. In Press.
2. Varkaris A, Corn PG, Efstathiou E, Aparicio A, Song JH, Zhou J, Parikh NU, Honage AG, Gaur S, Thorpe L, Maity SN, Czerniak BA, Lin S-H, Logothetis CJ, Gallick GE. Integration of murine and clinical trials links modulation of the tumor-associated microenvironment with cabozantinib efficacy in metastatic castrate resistant prostate cancer. In Press.
3. Maity SN, Wu G, Lu J-F, Hoang A, Landesman Y, McCauley D, Shacham S, Kauffman MG, Aparicio AM, Efstathiou E, Araujo JC, Logothetis CJ. In: Proceedings of the 105th Annual Meeting of the American Association for Cancer Research 55:Abstr 3808, 2014.
4. Efstathiou E, Deshpande H, George D, Joshua AM, Taplin M-E, Griffin TW, Londhe A, Mary Todd M, Molina A. An exploratory analysis of efficacy and safety of abiraterone acetate (AA) in black patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) without prior chemotherapy (ctx). In: Proceedings of the 105th Annual Meeting of the American Association for Cancer Research 55:Abstr 313, 2014.
5. Liu X-D, Yao J, Tripathi DN, Ding Z, Xu Y, Sun M, Zhang J, Bai S, German P, Hoang A, Zhou L, Zhang X, Conti CJ, Efstathiou E, Eissa TN, Mills GB, Walker CL, Jonasch E. Autophagy mediates HIF2α degradation and suppresses renal tumorigenesis. In: Proceedings of the 105th Annual Meeting of the American Association for Cancer Research 55:abstr 312, 2014.
6. Efstathiou E, Titus, MA Wen S, SanMiguel A, Hoang A, De Haas-Amatsaleh A, Perabo F, Phung D, Troncoso P, Ouatas T, Logothetis C. Enzalutamide (ENZA) in combination with abiraterone acetate (AA) in bone metastatic castration resistant prostate cancer (mCRPC). Oral Presentation. J Clin Oncol 32(5s):abstr 5000, 2014.
7. Dreicer R, Jones R, Oudard S, Efstathiou E, Saad F, De Wit R, De Bono JS, Shi Y, Tejura B, Agus DB, Borgstein NG, Bellmunt J, Fizazi K. Results from a phase 3, randomized, double-blind, multicenter, placebo-controlled trial of orteronel (TAK-700) plus prednisone in patients with metastatic castration-resistant prostate cancer (mCRPC) that has progressed during or following docetaxel-based therapy (ELM-PC 5 trial)-Oral Presentation. J Clin Oncol 32:Abstract No. 7^, 2014.
8. Moore WR, Maity SN, Eisner JR, Garvey EP, Hoekstra WJ, Titus MA, Logothetis C, Araujo JC, Efstathiou E, Schotzinger RJ. The enzymology of the selective CYP17 lyase inhibitor, VT-464, and its effects in castration-resistant prostate cancer (CRPC) models. J Clin Oncol 32(suppl 4):abstr 158, 2014.
9. Montgomery RB, Kheoh TS, Molina A, Li J, Bellmunt J, Ryan CJ, Tran N, Loriot Y, Efstathiou E, Scher HI, De Bono JS. Effect of corticosteroid (CS) use at baseline (CUB) on overall survival (OS) in patients (pts) receiving abiraterone acetate (AA): Results from a randomized study (COU-AA-301) in metastatic castration-resistant prostate cancer (mCRPC) post-docetaxel (D). J Clin Oncol 31:abstr 5014, 2013.
10. Bournakis E, Gyftaki R, Kafantari E, Razis E, Rigakos G, Stravodimos K, Mitropouos D, Bamias A, Dimopoulos MA, Efstathiou E. Enzulatamide (ENZA) in heavily pretreated patients with bone metastatic castration resistant prostate cancer (MCRPC) resistant to androgen biosynthesis inhibitor (ABI) treatment - the Hellenic experience of the Name Patient Access Program (NPAP). Ann Oncol 24:#2906, 2013.
11. Corn PG, Varkaris A, Tapia E L-N, Araujo JC, Aparicio A, Tu S-M, Zurita AJ, Efstathiou E, Qiao W, Wen S, Gallick GE, Logothetis C. Modulation of soluble c-Met, bone turnover markers, angiogenic factors, and c-Met in men with mCRPC treated with cabozantinib. J Clin Oncol 31(suppl 6):58, 2013.
12. Bamias A, Tsantoulis P, Zilli T, Koutsoukos K, Caparrotti F, Liontos M, Roth A, Lykka M, Stravodimos K, Chrisofos M, Papatsoris A, Efstathiou E, Wirth GJ, Mitropoulos D, Constantinides CA, Deliveliotis C, Iselin CE, Miralbell R, Dietrich P-Y, Dimopoulos MA. Outcome of patients with nonmetastatic, muscle-invasive bladder cancer (MIBC), not undergoing cystectomy, after treatment with non-cisplatin-based chemotherapy and/or radiotherapy: A retrospective analysis. J Clin Oncol 31:abstr e15619, 2013.
13. Araujo JC, Trudel GS, Saad F, Armstrong AJ, Yu EY, Bellmunt J, Wilding G, McCaffrey J, Serrano SV, Matveev V, Efstathiou E, Oudard S, Morris MJ, Sizer B, Goebell PJ, De Bono JS, Paliwal P, Durham S, Cheng S, Logothetis C. Overall survival (OS) and safety of dasatinib/docetaxel versus docetaxel in patients with metastatic castration-resistant prostate cancer (mCRPC): Results from the randomized phase III READY trial. J Clin Oncol 31(suppl 6):LBA8, 2013.
14. Ryan CJ, Kheoh T, Molina A, Carles J, Efstathiou E, Kantoff PW, Mulders PFA, Saad F, Griffin T, Chi KN. Prognostic index for progression-free survival in metastatic castration-resistant prostate cancer patients without previous chemotherapy: An analysis of the COU-AA-302. Ann Oncol 24:#2863, 2013.
15. Efstathiou E, Titus M, Wen AS, San Miguel A, Hoang A, De Haas-Amatsaleh A, Perabo F, Phung D, Troncoso P, Logothetis C. The effects of enzalutamide (ENZA) in combination with abiraterone acetate (AA) in patients with bone metastatic castration resistant prostate cancer (mCRPC). Ann Oncol 24:#2854, 2013.
16. Koutsoukos K, Liontos M, Lykka M, Rigakos G, Andreadou A, Efstathiou E, Koutras A, Papatsoris A, Chrisofos M, Stravodimos K, Adamakis I, Alamanis C, Karavasilis V, Makatsoris T, Galani EP, Klouvas G, Kosmidis PA, Fountzilas G, Dimopoulos MA, Bamias A. Two cycles of carboplatin as adjuvant therapy in stage I seminoma: 8-year experience by the Hellenic Co-operative Oncology Group (HECOG). J Clin Oncol 31:abstr 4558, 2013.
17. Efstathiou E, Assikis VJ, North SA, Showel J, Hutson TE, Riggs SB, Waxman J, Park YC, Kheoh TS, Haww CM, Logothetis C, Molina A. A hypothesis-generating exploratory analysis of efficacy and safety of abiraterone acetate (AA) in African American (Af Am) patients (pts) with metastatic castration-resistant prostate cancer (mCRPC). J Clin Oncol 30(suppl 5):56, 2012.
18. Efstathiou E, Davis JW, Troncoso P, Titus MA, Hoang A, Wen S, Zurita AJ, Tran N, Molina A, Logothetis C. Cytoreduction and androgen signaling modulation by abiraterone acetate (AA) plus leuprolide acetate (LHRHa) versus LHRHa in localized high-risk prostate cancer (PCa): Preliminary results of a randomized preoperative study. J Clin Oncol 30(suppl 5):4556, 2012.
19. Tzelepi V, Karlou M, Wen S, Hoang A, Scoupa C. Logothetis C, Efstathiou E, Troncoso. Differential expression of integrins in intraductal spread, cribriform, and non-cribriform patterns of high grade untreated and treated prostate cancer. Lab Invest 92(1s):1036, 2012.
20. Basch EM, De Bono JS, Scher HI, Molina A, Sternberg CN, Fizazi K, North SA, Chi KN, Jones RJ, Goodman OB, Mainwaring PN, Farr AM, Rothman M, Hao Y, Liu CS, Kheoh TS, Haqq CM. Logothetis C, Molina A. Pain control and delay in time to skeletal-related events (SRE's) in patients with metastatic castration-resistant prostate cancer (mCRPC) treated with abiraterone acetate (AA): Long-term follow-up. J Clin Oncol 30(suppl 5):183, 2012.
21. Droz J-P, Efstathiou E, Heidenreich A, Yildrim A, Cabrera P, Kim C-S, Horchani A, Rinck JA, Ozen H, for MATuRITY investigators. Taxane-based chemotherapy in senior adults with metastatic castration-resistant prostate cancer (mCRPC): A prospective international registry. J Clin Oncol 30(suppl 5):e15122, 2012.
22. Higano CS, Beer TM, Taplin M, Efstathiou E, Anand A, Hirmand M, Fleisher M, Scher HI, Prostate Cancer Clinical Trials Consortium. Antitumor activity of MDS3100 in pre- and post-docetaxel advanced prostate cancer: Long-term follow-up of a phase I/II study. J Clin Oncol 29(suppl 7):134, 2011.
23. Efstathiou E, Titus MA, Tsavachidou D, Hoang A, Karlou M, Wen S, Troncoso P, Ashe R, Berman CJ, Mohler J, Logothetis C. MDV3100 effects on androgen receptor (AR) signaling and bone marrow testosterone concentration modulation: A preliminary report. J Clin Oncol 29:4501, 2011.
24. Anand A, Scher HI, Danila DC, Beer TM, Higano CS, Taplin M, Efstathiou E, Hirmand M, Sawyers CL, Heller G. Circulating tumor cells (CTC) and prostate-specific antigen (PSA) as response indicator biomarkers in chemotherapy-naïve (CN) patients (pts) with progressive castration-resistant prostate cancer (CRPC) treated with MDV3100. ASCO Molecular Markers Meeting:39, 2010.
25. Anand A, Scher HI, Beer TM, Higano CS, Danila DC, Taplin M, Efstathiou E, Hirmand M, Sawyers CL, Heller G. Circulating tumor cells (CTC) and prostate-specific antigen (PSA) as response indicator biomarkers in chemotherapy-naïve (CN) patients (pts) with progressive castration-resistant prostate cancer (CRPC) treated with MDV3100. J Clin Oncol 28(18s):4546, 2010.
26. Tzelepi V, Efstathiou E, Troncoso P, Pettaway CA, Hoang A, Logothetis C, Pagliaro LC. Modulation of candidate therapy targets in regionally advanced prostate cancer by androgen ablation and docetaxel. J Clin Oncol 28(15s):4663, 2010.
27. Efstathiou E, Tu S, Aparicio A, Hoang A, Wen S, Troncoso P, Smith LA, Chieffo N, Molina A, Logothetis. Use of "intracrine androgen signaling signature" to predict benefit from abiraterone acetate (AA) in patients with castrate-resistant prostate cancer (CRPC). J Clin Oncol 28(15s):4547, 2010.
28. Ryan CJ, Efstathiou E, Smith M, Tapin M, Bubley G, Logothetis CJ, Kheoh T, Haqq CM, Molina A, Small EJ. Abiraterone acetate plus prednisone in chemotherapy (chemo)-naïve castration-resistant prostate cancer (CRPC) patients not exposed to ketoconazole: Results of a multicenter phase II study. ASCO Genitourinary Cancers Symposium(159), 2009.
29. Scher HI, Beer TM, Higano CS, Taplin M, Efstathiou E, Anand A, Hung D, Hirmand M, Fleisher M, The Prostate Cancer Clinical Trials Consortium. Antitumor activity of MDV3100 in a phase I/II study of castration-resistant prostate cancer (CRPC). J Clin Oncol 27(15s):5011, 2009.
30. Gorlov I, Byun JY, Forlova O, Efstathiou E, Logothetis C. Candidate pathways and genes for prostate cancer: a metra-analysis of gene expression data. Proc Amer Assoc Can Res 50:5205, 2009.
31. Efstathiou E, Wen S, Molina A, Chieffo N, Smith L, Hoang A, Troncoso P, Logothetis CJ. Candidate predictors of response to abiraterone acetate (AA) in castrate-resistant prostate cancer (CRPC). ASCO Genitourinary Cancers Symposium:187, 2009.
32. Scher HI, Beer T, Higano C, Efstathiou E, Anand A, Hirmand M, Hung D, Steve L, Fleisher M, Sawyers C. Clinical study of MDV3100 in progressive castration-resistant prostate cancer (CRPC). J Urol 181(4):641, 2009.
33. Ryan C, Efstathiou E, Smith M, Taplin M, Bubley G, Logothetis CJ, Kheoh T, Haqq C, Molina A, Small EJ. Phase II multicenter study of chemotherapy (chemo)-naïve castrate-resistant prostate cancer (CRPC) not exposed to ketoconazole (keto), treated with abiraterone acetate (AA) plus prednisone. J Clin Oncol 27(15s):5046, 2009.
34. Suleiman SH, Salim OE, Yousif DO, Eltahir MA, Elzaki K, Ibrahim SZ, Ahmed KM, Mudawi HM, Vini L, Silyvridou A, Kakana C, Janinis J, Diamantidou E, Navrozidou C, Boulogianni G, Hourmouzi D, Kopanakis K, Macheras A, Charalabopoulos A, Bistarakis D, Xylardistos P, Shizas D, Petropoulos K, Bakopoulos A, Liakakos T, Oikonomopoulos N, Martikos G, Patapis P, Misiakos E, Tsapralis D, Azas A, Charalobopoulos A, Liakakos L, Millo P, Allieta R, Nardi M, Brachet Contul R, Scozzari G, Alexandrou I, Lainakis N, Efstathiou E, Demetriadis D, Dolatzas T, Antypas S, Parini U, Persico F, Loffredo A, Lale Murix E, Fabozzi M, Roveroni M, Usai A, Da Broi J, Nardi MJ, Roustanis E, Benetatos N, Pappas-Gogos G, Tsimogiannis KE, Tsimoyiannis EC, Pramateftakis MG, Mantzoros I, Kanellos I, Demetriades H, Angelopoulos S, Despoudi K, Lazarides H, Tsachalis T, Sapidis N, Gouvas N, Tsiaoussis J, Pechlivanides G, Zervakis N, Xynos E. Abstracts Colorectal Games, Rethymnom, Crete, Greece, May 2008. Tech Coloproctol 12(3):267-71, 9/2008. PMID: 18798015.
35. Li ZG, Navone N, Yang J, Liu J, Mathew P, Starbuck M, Zurita A, Sikes C, Multani A, Efstathiou E, Lopez A, WAng J, Fanning T, Prieto V, Kundra V, Traoncoso P, Raymond A, Lin SH, Vazquez E. Androgen receptor-negative prostate cancer cells induce osteogenesis through FGF9-mediated mechanisms. Proc Amer Assoc Can Res 49:1612, 2008.
36. Logothetis CJ, Wen S, Molina A, Chieffo N, Smith LA, Troncoso P, Esftathiou E. Identification of an androgen withdrawal responsive phenotype in castrate resistant prostate cancer (CRPC) patients (pts) treated with abiraterone acetate (AA). J Clin Oncol 26:5017, 2008.
37. Efstathiou E, Tsavachidou D, Wen S, Troncoso P, Mills GB, Logothetis CJ. Integrated quantitative and spatial proteomic analysis of p13 kinase signaling in high grade prosate cancer (PCa) treated with temsirolimus with or without ablation. J Clin Oncol 26:5071, 2008.
38. Guo C, Cao D, Navone N, Efstathiou E, Maity S, Troncoso P, Czerniak B. TMPRSS2-ERG gene fusion in metastatic prostate cancer. Histopathology 53(s1):635, 2008.
39. Efstathiou E, Troncoso P, Wen S, Do K, Logothetis C. Coordinated modulation of sonic hedgehog (Shh) signaling and androgen receptor (AR) in the prostate tumor microenvironment by chemo-hormonal therapy. J Clin Oncol 25(18S):251 (#2065), 2007.
40. Efstathiou E, Logothetis CJ, Wen S, Do K, Troncoso P. Heterogeneity within High-Grade Adenocarcinoma of the Prostate: Implications for Molecular Diversity. ASCO Prostate Symposium, Annual meeting, 2007.
41. Efstathiou E, Wen S, Logothetis CJ, Do KA, McDonnell TJ, Troncoso P. Morphologic Heterogeneity within High-Grade Adenocarcinoma of the Prostate corresponds to molecular diversity. United States and CanadianAcademy of Pathology,, 2007.
42. Efstathiou E, Troncoso P, Pettaway C, Logothetis CJ. Coordinated modulation of pathways implicated stromal interaction by therapy in Prostate cancer. AACR Special Conference: Innovations in Prostate Cancer Research, 2006.
43. Efstathiou E, Troncoso P, Wen S, Do KA, Pettaway CA, Pisters LL, McDonnell TJ, Logothetis CJ. Initial Modulation of the Tumor Microenvironment Accounts for Thalidomide Activity in Prostate Cancer. Clin Cancer Res 13(4):1224-31, 2006. PMID: 17317833.
44. Εfstathiou E, Troncoso P, McDonnell TJ, Logothetis CJ. Thalidomide as a modulator of the stromal epithelial interaction of high-grade prostate cancer (PCa). NCI Prostate InterSPORE Meeting, 2006.
45. Kassar M, Yu Z, Bamias A, Markakis S, Kowalski D, Efstathiou E, Camp RL, Rimm DL, Psyrri D, Dimopoulos M. In situ proteomics of biomarker expression in epithelial ovarian cancer. J Clin Oncol(5041), 2005.
46. Kastritis E, Bozas G, Efstathiou E, Koutsoukou V, Gika D, Deliveliotis C, Antoniou N, Dimopoulos MA, Bamias A. Outcome of patients with advanced non-transitional urothelial carcinomas following platinum-based chemotherapy. J Clin Oncol:Abstract No 4596, 2005.
47. Mavroudis D, Efstathiou E, Polyzos A, Athanasiadis A, Milaki, Kastritis GE. A phase I-II trial of gefitinib in combination with vinorelbine and oxaliplatin as salvage therapy in women with advanced ovarian cancer (AOC). J Clin Oncol:Abstract No 5020, 2004.
48. Psyrri D, Bamias A, Yu Z, Markakis S, Kowalski D, Weinberger PM, Harigopal M, Efstathiou E, Rimm DL, Dimopoulos MA. Molecular predictors for response to carboplatinum and paclitaxel (CP) chemotherapy in patients with ovarian cancer. J Clin Oncol:Abstract 5066, 2004.
49. Bamias A, Efstathiou E, Hamilos G, Zorzou P, Bozas G, Gika D, Papadiitriou C, Dimopoulos MA. Outcome of elderly patients following platinum-based chemotherapy for advanced urothelial cancer. J Clin Oncol, 2004.
50. Efstathiou E, Papadimitriou C, Bamias A, Anagnostopoulos A, Zorzou MP, Kastritis E, Bozas G, Dimopoulos MA. Preliminary results of a Phase II study of the combination of biweekly cisplatin(CDDP) and gemcitabine as salvage therapy in patients with platinum refractory advanced ovarian cancer. European Society for Medical Oncology,30th meeting, 2004.
51. Dimopoulos MA, Anagnostopoulos A, Hamilos G, Zomas A, Efstathiou E. Pulsed cyclophosphamide, thalidomide and dexamethasone: Long Term Follow-Up of an Oral Regimen for Previously Treated Patients with Multiple Myeloma. American Society of Hematology, 45th Annual Meeting and Exposition, 12/2003.
52. Εfstathiou E, Dimopoulos MA. Τhe combination of carboplatin gemcitabine in elderly patients with advanced urothelial carcinoma. Global Investigator Meeting on new drugs, 2003.
53. Εfstathiou E, Dimopoulos MA. Objective and lasting response in chemorefractory metastatic NSCLC by IRESSA administration. ICE MEETING, 2003.
54. Anagnostopoulos A, Efstathiou E, Hamilos G, Zorzou MP, Kastritis E, Dimopoulos MA. Patterns of progression in Myeloma Patients Treated with Thalidomide-Based Regimens: High Incidence of Extramedullary Progression without Serological Response. American Society of Hematology 45th Annual Meeting and Exposition, 2003.
55. Dimopoulos MA, Zomas A, Tsatalas K, Hamilos G, Efstathiou E, Gika D. Thalidomide-based treatment for Waldenstrom’s macroglobulinemia. 2nd International Workshop on Waldenstrom’s Macroglobulinemia, 2003.
56. Meletios A Dimopoulos, Christos Papadimitriou, E. Efstathiou, C. Kiamouris, A. Anagnostopoulos, D. Bafaloukos, D. Skarlos, G. Aravantinos, G Fountzilas. Adjuvant treatment of early ovarian cancer with four courses of paclitaxel and carboplatin: a phase II study of the Hellenic Cooperative Oncology Group. J Clin Oncol:Abstract No: 2522, 2002.
57. H. Linardou, G. Aravantinos, H. Kalofonos, E. Efstathiou, A. Bamias, G. Chamilos, D. Bafaloukos, E. Razis, M.A. Dimopoulos. Gemcitabine and carboplatin combination as first-line treatment of advanced urothelial carcinoma: Activity in elderly, unfit patients. A phase II study of the Hellenic Co-operative Oncology Group. European Society for Medical Oncology,29th Meeting, 2002.

Book Chapters

1. E. Efstathiou, CJ Logothetis. “Clinical challenges for treatment and a cure” (Chapter V). In: “The Biology and Treatment of Cancer”. John Wiley & Sons, 2006.

Grant & Contract Support

Title: MD Anderson Cancer Center Prostate Cancer SPORE
Funding Source: NIH/NCI
Role: Co-Investigator
Principal Investigator: Logothetis-Thompson
Duration: 5/1/2015 - 4/30/2020
 
Title: Mechanisms of resistance to androgen biosynthesis inhibition in castrate-resistant prostate cancer bone metastases
Funding Source: Prostate Cancer Foundation
Role: Co-Investigator
Principal Investigator: Christopher J. Logothetis
Duration: 6/2011 - 5/2013
 
Title: Individualized microenvironment targeted therapy for prostate cancer bone metastases: Simultaneous evaluation of multiple therapeutic targets
Funding Source: Prostate Cancer Foundation
Role: Co-Investigator
Principal Investigator: Christopher J. Logothetis
Duration: 1/2010 - 12/2011
 
Title: Exploring the heterogeneity of androgen signaling in prostate cancer progression
Funding Source: Prostate Cancer Foundation
Role: Co-Investigator
Principal Investigator: Christopher J. Logothetis, MD
Duration: 4/2008 - 3/2011
 
Title: Maximizing therapeutic potential: An exploratory study to identify predictors of response and resistance to maximal androgen blockade in prostate cancer
Funding Source: Prostate Cancer Foundation
Role: Principal Investigator
Duration: 4/2008 - 3/2011

Last updated: 7/9/2014